GeNeuro: financial information and business update for the first quarter 2020

Geneva, Switzerland, April 27, 2020 – 7.30am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), today reported on its 2020 first quarter cash position and issued a business update.